MEDP
T2Medpace Holdings, Inc.
Biotech '26: AI Driven Drug DiscoveryMedTech Long '26: CROsMedTech Short '25: High Val MedTechRegulatory Testing '26: Life Sciences & Lab Tests
OverviewMedpace Holdings, Inc. is a contract research organization (CRO) providing comprehensive clinical development and research services, from Phase I to IV, for pha
Medpace Holdings, Inc. is a contract research organization (CRO) providing comprehensive clinical development and research services, from Phase I to IV, for pharmaceutical, biotechnology, and medical device clients. They primarily serve smaller companies. While metabolic work previously drove growth, oncology now represents over half of new bookings and awards. Their top 10 customers account for approximately 40% of their last 12 months' revenue.
- What They Do (Plain English & Analogies)
- Medpace acts like a specialized outsourced research and development department for companies that are creating new medicines, medical devices, or other health treatments. Instead of these pharmaceutical, biotechnology, and medical device companies doing all the complex and time-consuming testing themselves, they hire Medpace. Medpace handles the entire process of clinical trials, from the very first tests in humans (Phase I) all the way through to post-market support (Phase IV). This includes designing the studies, managing patient data, ensuring everything follows strict government rules, running the trials, analyzing the results, and providing specialized lab testing like bio-analytical, ECG, and imaging services. Essentially, they help bring new treatments to market faster and more efficiently by providing a comprehensive, integrated platform for clinical research. [6, 7, 8, 9, 10]
- Very Brief History
- Medpace Holdings, Inc. was founded in Cincinnati, Ohio, in 1992. Over the years, it has evolved into a global contract research organization (CRO) providing a comprehensive suite of clinical development and research services across various therapeutic areas.
- "Street Stereotype"
- The 'Street stereotype' for Medpace often involves scrutiny over its valuation, with investors perceiving it as having a premium multiple. This perception is amplified by recent concerns about slowing sequential growth and a declining backlog coverage beyond the next 12 months. The market is particularly focused on whether Medpace's growth trajectory can justify its valuation, especially given the recent negative reaction to booking trends and future growth prospects.
- Subsidiaries On Linked In*
- {"subsidiaries":[]}
- Customer Sectors & Example Clients
- Medpace's customers are primarily in the pharmaceutical, biotechnology, and medical device industries. They specifically focus on serving virtual and smaller companies, rather than large pharmaceutical firms. While specific client names are not disclosed due to confidentiality, their customer base consists of numerous small to mid-sized biotech and pharma firms developing new therapies and devices.
- New Customers / Segments They'Re Targeting
- Medpace is not explicitly targeting entirely new customer types or geographical segments. Instead, the company is seeing a shift in the therapeutic areas driving new business awards. Oncology has significantly rebounded, representing over half of their overall bookings and award notifications in Q2 2026, while cardiometabolic opportunities have decreased in terms of new award notifications. Management is focused on expanding its pipeline of opportunities and improving its win rate within its existing global footprint and client base. [transcript]
- Supply Chain And Sourcing Geographies
- As a Contract Research Organization (CRO), Medpace's 'supply chain' primarily involves its global network of clinical research professionals, laboratories, and clinical trial sites. The company operates across North America, Europe, and Asia. More specifically, Medpace has a global presence with operations in countries including the US, UK, Germany, France, Italy, Spain, Poland, Czech Republic, Hungary, Romania, Russia, Ukraine, Israel, South Africa, India, China, Japan, South Korea, Taiwan, Australia, Argentina, Brazil, Canada, Mexico, and Peru. Their services are delivered through these global operations, leveraging local expertise and resources for clinical trials.
- Sales Geographies And Expansion Plans
- Medpace currently sells its services geographically across North America, Europe, and Asia. The company also has a presence in Latin America and South Africa. Management has not indicated specific plans to expand sales into new geographies, but rather focuses on expanding its pipeline and improving its win rate within its existing global footprint. [2]
- How Key Themes May Help/Hurt
- The buildout of 'AI Driven Drug Discovery' presents both opportunities and challenges for Medpace. As a CRO, Medpace can benefit from AI's ability to reduce drug development timelines and costs, potentially leading to more efficient trials and a higher volume of projects from clients leveraging AI in their discovery phases. AI can enhance data quality, trial efficiency, and the adoption of digital endpoints in clinical trials, which Medpace can integrate into its service offerings. [Theme_BullBearDetails] However, Medpace anticipates significant upfront capital investment in AI over the next two years, with net benefits in efficiency not expected for a few years out. This initial investment could impact near-term profitability. [transcript] The evolving regulatory landscape for AI-designed drugs also creates uncertainty, which Medpace, as a regulatory expert, will need to navigate for its clients. [Theme_UpcomingCatalysts]
3 Main Long-Term Bull Details
- Specialized Full-Service Model: Medpace's comprehensive, internally-driven, full-service model for clinical development is highly valued by smaller and virtual biotech companies, allowing them to outsource complex R&D efficiently and providing a single, accountable partner for clinical research, data, labs, and regulatory support. [2, 6, 10]
- Strong Financial Performance & Cash Generation: The company has demonstrated robust financial performance, with significant revenue and EBITDA growth, strong cash flow from operating activities, and a healthy cash balance, indicating operational efficiency and financial stability. [13]
- High-Quality Opportunity Flow & Improving Business Environment: Despite past fluctuations, Medpace is experiencing a strong business environment with record net bookings, reduced cancellations, and increasing RFPs of good quality, suggesting sustained demand for its specialized services and a healthy pipeline for future growth. [transcript]
3 Main Long-Term Bear Details
- Backlog Volatility and Conversion Rate: While Q2 2026 saw an improved net book-to-bill ratio, concerns about the long-term backlog coverage persist. The backlog conversion rate, while high, is influenced by policy implementations regarding decision points in trials, and its future trajectory is uncertain, potentially impacting future revenue visibility. [transcript]
- Exposure to Biotech Funding Volatility and M&A Impact: Medpace's client base, primarily smaller and virtual biotechs, is inherently sensitive to fluctuations in capital markets and biotech funding. Additionally, client acquisitions by larger pharmaceutical companies can be detrimental, as acquired clients may cut Medpace out of future work, creating ongoing competitive pressure. [transcript]
- Initial AI Investment Outweighs Near-Term Benefits: Management expects to invest significantly in AI over the next two years, with the anticipation of net benefits in efficiency only a few years down the line. This substantial upfront capital investment could create a drag on near-term profitability and operational efficiency before long-term gains are realized. [transcript, Theme_BullBearDetails]
- Competitors And Differentiation
- Medpace operates in a highly competitive CRO market. Its key competitors include larger, more diversified CROs such as IQVIA, ICON, Labcorp (which includes Fortrea), Charles River Laboratories, Thermo Fisher Scientific (through its PPD division), Syneos Health, and Parexel. [1, 2, 3, 4, 5] Medpace differentiates itself through a scientifically-driven, full-service model, emphasizing deep scientific focus and close trial execution, particularly appealing to biotech and mid-sized pharma clients. [2, 10] They are often perceived as more focused and less bureaucratic than some larger rivals, prioritizing service quality, scientific discipline, and execution consistency over mass-market reach or being the lowest-cost provider. [2]
- Recent Performance & What The Market'S Focused On
- Medpace reported a strong second quarter in 2026, with revenue of $707.3 million, a 17.2% increase year-over-year. Net new business awards were a record $795.7 million, up 28.2% from the prior year, resulting in a healthy 1.13x net book-to-bill ratio. Ending backlog as of June 30, 2026, was approximately $3 billion, an increase of 4.9% from the prior year. A significant driver of the strong net bookings was a substantial reduction in cancellations compared to the previous quarter. The company also updated its full-year 2026 guidance upwards for total revenue, EBITDA, net income, and diluted EPS. [transcript, 13] The market is focused on the sustainability of the improved cancellation rates, the shift in booking mix back towards oncology from cardiometabolic, the backlog conversion rate dynamics, and the long-term impact and investment required for AI initiatives. [transcript]
- Revenue Segments And Estimated Mix
- Oncology — Mix: Over 50% of Q2 2026 bookings and award notifications; Source: Q2 2026 earnings transcript; Trend: Strong comeback in Q2 2026, moving back towards historical averages and retaking its position as the largest segment in new awards.
- Cardiometabolic (including GLP-1 related work) — Mix: Significant segment, but declining in new awards; Source: Q2 2026 earnings transcript; Trend: New award notifications have dropped off quite a bit in Q2 2026 compared to a year ago, with large programs reducing. Historically had the lowest cancellation rate.
- Product Brands
- {"brands":[]}
Bull / Bear DetailsMedpace Holdings, Inc. demonstrates renewed momentum as of July 23, 2026, with record Q2 net bookings, a robust 1.13x book-to-bill ratio, and significantly redu
Thesis
Medpace Holdings, Inc. faces significant headwinds as of April 24, 2026, with elevated backlog cancellations and a weak net book-to-bill ratio impacting future growth visibility. While current revenue growth remains strong and management is implementing initiatives to improve win rates, the consistent decline in long-term backlog and acknowledged concerns about 2027 sequential growth reinforce a bearish outlook for this high-valuation MedTech name, aligning with the 'MedTech Short '25' theme.
Bull case
Despite facing headwinds, Medpace reported robust revenue growth of 26.5% year-over-year in Q1 2026, and management reconfirmed its full-year 2026 guidance. This indicates confidence in the company's ability to execute on existing projects and manage near-term challenges, suggesting that current operational strength can partially offset booking volatility.
Medpace is actively implementing initiatives to expand its pipeline of opportunities and improve its win rate. Management believes these strategic efforts will combat higher cancellation rates and drive future gross awards, potentially leading to a rebound in bookings and a more favorable book-to-bill ratio in upcoming quarters.
The quality of Medpace's opportunity flow remains good, with strong initial award notifications and win rates. Furthermore, the metabolic/GLP-1 therapeutic area, a significant growth driver, has historically shown the lowest cancellation rates, suggesting resilience and stability in a key segment of its client base.
Bear case
Medpace experienced its highest backlog cancellations in over a year during Q1 2026, resulting in a net book-to-bill ratio of 0.88. This indicates that new business awards are not keeping pace with revenue recognition, leading to a contraction of the backlog and posing a significant threat to future revenue growth.
The company's backlog coverage beyond 12 months has declined for six consecutive quarters, and management explicitly stated that sequential growth in 2027 is a "real question." This diminishing long-term visibility signals structural challenges in securing new business and converting awards into recognized revenue, raising concerns about sustained growth.
RFP volume was down sequentially and year-over-year in Q1 2026, suggesting potential future weakness in gross awards. Additionally, biopharma M&A activity is generally detrimental to Medpace, as acquired clients often cut them out of future work, creating ongoing competitive pressure and limiting growth opportunities.
Bull / Bear Case
- Bear Case
- Despite the strong Q2 performance, Medpace faces inherent unpredictability regarding future cancellations, which management explicitly states are "completely beyond my ability to even [predict]," posing a significant risk to net bookings and backlog stability. The current backlog conversion rate of 24.1% is high relative to historical values, and management anticipates it will "tend to drop down some over time," potentially decelerating future revenue recognition. Customer concentration remains a concern, with the top 10 clients accounting for approximately 40% of last twelve months' revenue, introducing client-specific execution and funding risks. Additionally, while AI investments are planned, management expects significant upfront capital investment over the next two years, with net benefits in efficiency only anticipated a few years out, which could create a drag on near-term profitability. Insider selling of $7.4 million in shares over the past three months also suggests caution among insiders.
- Bull Case
- Medpace demonstrated strong operational momentum in Q2 2026, reporting record net bookings of $795.7 million, a 28.2% year-over-year increase, and a robust 1.13x net book-to-bill ratio. This signals healthy demand and a strong pipeline for future revenue. The business environment has significantly strengthened, with cancellations "well behaved" and substantially reduced from Q1's elevated levels, driving over half of the net bookings increase. Management also upgraded its full-year 2026 guidance for revenue, EBITDA, net income, and EPS, reflecting increased confidence. Furthermore, a favorable shift in therapeutic mix is observed, with oncology now representing over half of new bookings and awards, diversifying away from prior metabolic concentration. The company's pre-backlog is larger than its backlog and growing faster, indicating a strong future opportunity pipeline.
- More Compelling & Why
- Given Medpace's current P/E ratio of 38.5x, which is a premium valuation reflecting high growth expectations, the **Bear Case** is currently more compelling. While Q2 results were strong, the stock has already surged significantly (16.9% on July 23, 2026), and the premium valuation is not fully justified by the inherent unpredictability of future cancellations and the expected normalization of the high backlog conversion rate. The strongest argument for the bear case is management's explicit statement about the unpredictability of cancellations and the expectation for the high backlog conversion rate to "tend to drop down some over time," which directly impacts future revenue visibility and growth. My view would flip to bullish if the company could demonstrate sustained low cancellation rates and a stable, high backlog conversion rate for at least two more quarters, alongside a more attractive valuation relative to its growth prospects.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Quarterly Net Book-to-Bill Ratio | A ratio above 1.0 indicates that new business awards are outpacing revenue recognition, leading to backlog expansion and supporting future revenue growth. | The quarterly net book-to-bill ratio. Monitor if it remains consistently above 1.0, specifically at or above the Q2 2026 ratio of 1.13x. | Bullish if the net book-to-bill ratio remains consistently above 1.0, especially at or above 1.13x. Bearish if the ratio consistently falls below 1.0. | Medpace's quarterly earnings press releases and conference calls. Next update: Q3 2026 earnings call (expected October 2026). | ||
| Backlog Coverage Beyond 12 Months | This metric provides visibility into Medpace's longer-term revenue pipeline, indicating the sustainability of growth beyond the immediate fiscal year. | The absolute dollar value of backlog projected to convert beyond the next 12 months. Monitor if this figure stabilizes or increases from the Q2 2026 level of $1.04 billion (calculated as $3 billion total backlog - $1.96 billion converting in next 12 months). | Bullish if the dollar value of backlog converting beyond 12 months stabilizes or increases from $1.04 billion. Bearish if it declines, indicating diminishing long-term visibility. | Medpace's quarterly earnings press releases and conference calls. Next update: Q3 2026 earnings call (expected October 2026). | ||
| RFP Volume and Quality of Opportunities | RFP volume and quality are leading indicators of future gross awards and overall business health, reflecting client demand and market strength. | Management commentary on sequential and year-over-year RFP volume trends and the quality of opportunities, including client funding status and initial award notifications. Specifically, watch for continued reports of 'high quality opportunities' and 'constructive' environment into July. | Bullish if management reports sustained or increasing RFP volume, high-quality opportunities, and strong client funding. Bearish if RFP volume declines or quality deteriorates. | Medpace's quarterly earnings conference calls and press releases. Next update: Q3 2026 earnings call (expected October 2026). | ||
| Quarterly Backlog Cancellation Rate | Elevated cancellations directly reduce future revenue from existing contracts, signaling pressure on future growth. A decrease indicates improved client stability and better revenue visibility. | The quarterly backlog cancellation rate as a percentage of beginning backlog. Monitor if the rate remains at or below the Q2 2026 'very good level' reported by management, or shows a sustained downward trend. | Bullish if the cancellation rate remains at or below the Q2 2026 level, or shows a sustained downward trend from Q1 2026's elevated levels. Bearish if the rate increases back towards or above Q1 2026 levels. | Medpace's quarterly earnings conference calls and press releases. Next update: Q3 2026 earnings call (expected October 2026). | ||
| Net New Business Awards (Net Bookings) | Net bookings represent new business secured after cancellations, directly impacting backlog growth and future revenue generation. Strong bookings are crucial for sustained growth. | The absolute dollar value of net new business awards and its year-over-year growth. Specifically, monitor if the growth rate sustains or exceeds the Q2 2026 increase of 28.2% ($795.7 million). | Bullish if net new business awards show sustained year-over-year growth (e.g., above 20%) and management projects continued ramp-up in gross bookings in the second half of 2026. Bearish if growth decelerates significantly or turns negative. | Medpace's quarterly earnings press releases and conference calls. Next update: Q3 2026 earnings call (expected October 2026). |
Key Reported Metrics, Reratings Triggers & ResultsThis ratio is crucial for future revenue visibility. An improvement above 1.0 indicates new business awards are outpacing revenue recognition, signaling healthy
| Key reported metrics | Rerating thresholds | Earnings results | ||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date | Actual reported | Hit target? | Notes |
| Net Book-to-Bill Ratio | 28.2% | This ratio is crucial for future revenue visibility. An improvement above 1.0 indicates new business awards are outpacing revenue recognition, signaling healthy backlog growth and future revenue potential. | For a lower rerating (bearish confirmation), Medpace's Net Book-to-Bill Ratio needs to remain at or below 0.88%. A failure to significantly improve from the current -2.22% and a continued ratio below 1.0, particularly at or below the Q1 2026 level of 0.88x, would reinforce the bearish outlook. | A Net Book-to-Bill Ratio at or below 0.88% signals that new business awards are not keeping pace with revenue recognition, leading to further backlog contraction. This diminishes future revenue growth visibility and reinforces concerns about Medpace's long-term growth profile and its ability to justify its premium valuation, especially when peers are reporting stronger booking trends. | 1.13x | Yes | The net book-to-bill ratio improved significantly to 1.13x in Q2 2026, up from 0.88x in Q1 2026. This indicates that new business awards are outpacing revenue recognition, a positive development that surpasses the rerating trigger for avoiding a bearish confirmation. | |
| Net Income per Diluted Share | 37.1% | A key measure of profitability on a per-share basis, reflecting the company's efficiency and value creation for shareholders. Strong growth indicates effective cost management and higher earnings. | ||||||
| Total Revenue | 17.2% | A primary indicator of operational performance and market demand. Investors will monitor if Medpace can sustain its growth trajectory amidst evolving business dynamics and booking trends. | Total Revenue growth for Q2 2026 that is below the low end of the company's full-year 2026 guidance range of 8.9% year-over-year, or a downward revision of the full-year 2026 revenue guidance of $2.755 billion to $2.855 billion. | This threshold matters because Medpace's current high valuation is predicated on its historical growth trajectory. A significant deceleration in Total Revenue growth, particularly below its own reconfirmed guidance, would confirm existing concerns about elevated backlog cancellations, a weak net book-to-bill ratio, and declining long-term backlog coverage. This would signal that booking trends are indeed impacting recognized revenue, justifying a lower rerating as the company's growth profile would no longer support its premium multiple. | $707.3 million (17.2% y/y growth) | Yes | Medpace reported Q2 2026 revenue of $707.3 million, representing a 17.2% year-over-year increase, which is well above the 8.9% low end of the previous full-year guidance growth rate. Furthermore, the company raised its full-year 2026 revenue guidance to a range of $2.805 billion to $2.885 billion, representing 10.9% to 14% growth over 2025, from the prior range of $2.755 billion to $2.855 billion. This upward revision and strong Q2 growth indicate the company exceeded the rerating trigger. | |
Key QuestionsCan Medpace sustain the improved net book-to-bill ratio above 1.0 and maintain lower backlog cancellation rates in the coming quarters, especially given the exp
Can Medpace sustain the improved net book-to-bill ratio above 1.0 and maintain lower backlog cancellation rates in the coming quarters, especially given the expected ramp in gross bookings?
- Question 2
Will Medpace's efforts to position the business for 2027 translate into strong and sustained sequential revenue growth, further increasing backlog coverage beyond 12 months?
- Question 3
How will the shift in new awards and bookings mix towards oncology, and away from metabolic work, impact Medpace's overall gross bookings growth and profitability in the coming quarters?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Positioning the business for 2027: Management is making good progress in positioning the business for 2027, indicating a forward-looking strategy beyond the current fiscal year. 2. Ramping up gross bookings: Management expects a ramp in gross bookings in the second half of 2026, which they anticipate will translate into a ramp in net bookings. 3. Employee growth and retention: The company is focused on maintaining low employee turnover and expects high single-digit employee growth this year, indicating a stable and growing workforce. | The overall takeaway from the call is one of cautious optimism. Management reported a strong business environment in Q2 2026, characterized by record net bookings and a significant improvement in cancellation rates compared to the prior quarter. While revenue growth was solid, there's a clear acknowledgment of a shift in new awards from metabolic back towards oncology, and ongoing discussions around the dynamics of backlog conversion rates and future growth trajectory. Management is focused on ramping gross bookings in the second half of the year and strategically positioning the business for 2027, indicating a forward-looking but measured approach. | Total revenue increased 26.5% year-over-year in Q1 2026. Segment-specific year-over-year growth rates were not reported for the prior quarter. | 1. Metabolic work concentration and customer concentration: Analysts questioned if metabolic work was driving the concentration of top 5 customers and sought visibility on this trend. Management confirmed that metabolic work has significantly driven top 5 customer growth, but noted a shift with oncology coming back strong in new award notifications and bookings, while new metabolic opportunities have decreased. They expect a return to more historical mix averages over the next year or so. 2. Backlog conversion rate: Analysts pressed on the high backlog conversion rate and whether the metabolic mix was a primary driver. Management clarified that metabolic programs are not the overwhelming driver of the increased conversion rate. Instead, the higher rate is attributed more to their policy of limiting backlog recognition until decision points and the average age of projects. They anticipate the conversion rate will 'tend to drop down some over time'. 3. Cancellations: Analysts inquired about the trend of cancellations, asking if they had improved and their impact on bookings. Management reported that cancellations were 'well behaved' in Q2 2026, representing a substantial drop from Q1, and were more than half the driver of the net bookings increase from the prior quarter. They stated they cannot predict future cancellations but expect gross bookings to ramp up in the second half, which should lead to ramping net bookings if cancellations remain within a 'reasonable range'. | Total revenue increased 17.2% year-over-year in Q2 2026. Segment-specific year-over-year growth rates were not reported in the transcript. |
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Expanding the pipeline of opportunities and improving the win rate: Management is focused on implementing initiatives to expand their pipeline and improve their win rate to combat higher cancellation rates. 2. Maintaining 2026 revenue guidance: Despite headwinds from cancellations and a sub-1 book-to-bill ratio, management reconfirmed their 2026 guidance, expressing confidence in their current modeling. 3. Investing in AI for future benefits: Management believes AI holds value but expects significant investment over the next two years, with net benefits in efficiency anticipated a few years out. | The overall takeaway from the call is one of caution regarding future growth, tempered by management's determined efforts to address current challenges. The tone was mixed, with management acknowledging significant headwinds such as the highest backlog cancellations in over a year and a weak net book-to-bill ratio of 0.88. However, they expressed confidence in maintaining their 2026 revenue guidance and highlighted ongoing initiatives to expand the opportunity pipeline and improve win rates. There's an explicit acknowledgment that sequential growth is a 'real question' for 2027, indicating a more conservative outlook for the longer term if current trends persist. | For the fourth quarter of 2025, Medpace reported an overall revenue increase of 32.0% year-over-year. No specific segment revenue growth figures were provided for the prior quarter. | 1. Cancellations: Analysts repeatedly questioned the dynamics, drivers, therapeutic areas, and Q2 trends of the elevated cancellations. Management responded that cancellations were due to 'random stuff' like product performance and reprioritizations, not macro-related, with oncology and cardiovascular being the largest therapeutic areas. They stated it was too early to assess Q2 cancellation rates. 2. GLP-1/Metabolic concentration and volatility: Analysts inquired about Medpace's exposure to GLP-1 and metabolic studies and whether this concentration was leading to increased volatility or cancellations. Management clarified that metabolic historically has the lowest cancellation rate among therapeutic areas and that GLP-1 work is 'pretty safe' and 'going fine,' despite potential market saturation impacting new opportunities. 3. Backlog decline and future growth profile: Analysts expressed concern over the declining backlog coverage beyond one year and its implications for future revenue growth. Management acknowledged this as an 'area for concern,' stating that sequential growth in 2027 is a 'real question' and that they need either cancellations to abate or gross awards to increase to achieve a desired growth rate. | Medpace reported total revenue of $706.6 million for the first quarter of 2026, representing a year-over-year increase of 26.5% (25.8% on a constant currency basis). No specific revenue segments with year-over-year growth were reported in the transcript. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| RFPs were up sequentially and year over year, generating high quality opportunities. Initial award notifications remained solid although they declined sequentially from a very strong Q1. The overall environment remains constructive into July, and Medpace is making good progress in positioning the business for 2027. The business environment continued to be strong, and new opportunities look good. The company's pipeline of pre-backlog awarded programs is very strong. RFP numbers have increased substantially year over year and sequentially by a reasonable amount, with quality being more important and consistently good. Medpace is seeing a broader range of clients with recent funding, leading to more opportunities and programs moving forward. | Medpace does not see a change in competitive dynamics, stating that the market has gotten stronger. The company acknowledged that its win rate in 2025 was lower than in prior years and that changes were made in late 2025 and early Q1 2026 to address this, which may have influenced the strong win rate in Q1. | Growth over the last year has been significantly driven by metabolic work, particularly from a few large clients. However, oncology has seen a strong comeback in award notifications and bookings in Q2 2026, representing over half of overall bookings and award notifications. Metabolic/cardiometabolic new award notifications have dropped off, indicating a shift back towards more historical averages, with oncology expected to retake its position in the mix over the next year or so. Medpace does not observe a significant shift of Phase 2 trials to China for the programs it is pursuing. Many clients are raising money concurrently with seeking bids for programs. | The business environment is expected to remain constructive into July, with good progress in positioning for 2027. Medpace anticipates a shift back towards historical therapeutic area mixes, with oncology regaining a larger share over the next year. Gross bookings are expected to scale and ramp up in the second half of the year, which should translate into a ramp in net bookings, assuming cancellations remain within a reasonable range. Full-year 2026 total revenue is now expected in the range of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14% over 2025. EBITDA is projected between $618 million and $642 million, and net income between $494 million and $514 million. Earnings per diluted share are expected to be in the range of $17.25 to $17.95. The reimbursable component of direct costs is expected to decline further in the back half of the year, modeled at 41% to 42% of revenue for Q3 and Q4. Margin expansion is anticipated in the second half due to headcount increases at a slower pace than revenue. The backlog conversion rate is expected to trend downward over time towards historical norms, influenced by the average age of projects and booking characteristics. | CROs: | The business environment was strong in Q2 26. Cancellations were well behaved, and supported a record quarter for net bookings. RFPs were up sequentially and year over year, generating high quality opportunities. Overall, the environment remains constructive into July. Net new business awards entering backlog in the second quarter increased 28.2% from the prior year. Oncology represented over half of our overall bookings and our award notifications. Our pipeline of stuff... is very strong. Cancellations were actually in a pretty good range this quarter. We are seeing more opportunities with you know, recent funding and moving forward with the program. I think we are in a good place. | Initial award notifications remained solid although they declined sequentially from a very strong Q1. Metabolic cardiometabolic has kinda dropped off quite a bit. Cancellations are completely beyond my ability to even yeah. Cancellations are always a wild card. I do not know that it is gonna come down. | The impact of higher reimbursable costs was offset primarily by lower employee related costs in Q2 2026. Headcount growth ticked up slightly, and Medpace believes it is in a good place, substantially helped by low turnover which continued through Q2. The company expects high single-digit growth in employees this year and anticipates this to continue next year. Employee growth has been predominantly in the U.S. and Asia-Pac, with a chunk in India for cost positioning. The biggest growth has been in the U.S., with some repositioning occurring. Headcount increases in the back half of the year are expected to be at a slower pace than revenue, contributing to margin expansion. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Medpace is focused on expanding its pipeline of opportunities and has implemented a number of initiatives to improve its win rate to combat higher cancellation rates. The company believes there are opportunities to expand both the pipeline and the win rate to achieve a desired growth rate. | The market is very competitive, and Medpace aims to improve its win rate, though it is unclear if increased competitiveness is the direct cause of recent trends. The company has not seen a large change in the competitive landscape. | Biopharma M&A is generally not good for Medpace, as acquired clients often cut them out of future work, though ongoing projects usually continue. RFP volume was down sequentially and year-over-year. While biotech funding has remained stable, Medpace does not see widespread funding problems or clients merely seeking bids for fundraising purposes. The GLP-1 market, despite becoming saturated and competitive, has not resulted in higher cancellations for Medpace, and metabolic studies historically have the lowest cancellation rate among therapeutic areas. Oncology and cardiovascular were the largest therapeutic areas for cancellations in Q1 2026, which is considered usual. | Medpace's 2026 guidance ranges for revenue, EBITDA, net income, and EPS are unchanged from the prior quarter. However, the company's growth profile in terms of sequential growth for both now and six months from now is a 'real question'. Medpace needs either cancellations to abate or gross awards to increase to restore a desirable growth rate. The company anticipates improving bookings over time. Pass-throughs as a percentage of revenue are expected to end the year lower than the first quarter. Regarding AI, Medpace expects to invest more dollars in trying to achieve future benefits over the next two years than it will gain in efficiency, with net benefits anticipated a few years out. | CROs: | AI Driven Drug Discovery | We continue to view the quality of opportunity flow as good. Initial award notifications and win rate were strong. We feel very good about the range that we have out there, which is why we reconfirmed guidance. We're still hiring. I don't know how you get any more confident than that. | Quarter 1 of 2026 saw cancellations rise again with backlog cancels reaching their highest point in over a year. Net bookings were below the level of -- seen in Q4, but well above those in Q1 2025 with a net book-to-bill ratio of 0.88. RFPs were down in the quarter sequentially and year-over-year. Acquisitions are not good for us? No, but it happens all the time. Certainly, what we consider a reasonable growth rate is not projected on a sequential basis going forward. | Medpace is continuing to hire, which management views as a signal of confidence despite cancellations and softer gross wins. Lower employee-related costs primarily offset the impact of higher reimbursable costs in the first quarter. Improved retention rates are contributing to operating efficiencies, though perhaps at a slower pace. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Medpace is focused on expanding its pipeline of opportunities and has implemented a number of initiatives to improve its win rate to combat higher cancellation rates. | The market is very competitive, and Medpace aims to improve its win rate, though it's unclear if increased competitiveness is the direct cause of recent trends. | Biopharma M&A is generally not good for Medpace, as acquired clients often cut them out of future work, though ongoing projects usually continue. While biotech funding has remained stable, RFP weakness was observed, but Medpace does not see widespread funding problems or clients merely seeking bids for fundraising purposes. The GLP-1 market, despite becoming saturated and competitive, has not resulted in higher cancellations for Medpace, and metabolic studies historically have the lowest cancellation rate. | Medpace needs cancellations to abate or gross awards to increase to restore a desirable growth rate, as sequential growth is currently a concern. The company anticipates improving bookings over time. Pass-throughs as a percentage of revenue are expected to end the year lower than the first quarter. AI is expected to require significant investment over the next two years, with actual net benefit on efficiency still a few years out. | Regarding | AI (Artificial Intelligence) | We continue to view the quality of opportunity flow as good. Initial award notifications and win rate were strong. We feel very good about the range that we have out there, which is why we reconfirmed guidance. We're still hiring. I don't know how you get any more confident than that. I believe we have very high-quality opportunities, and I haven't seen a deterioration of that. | Quarter 1 of 2026 saw cancellations rise again with backlog cancels reaching their highest point in over a year. Net bookings were below the level of -- seen in Q4, but well above those in Q1 2025 with a net book-to-bill ratio of 0.88. RFPs were down in the quarter sequentially and year-over-year. Acquisitions are not good for us? No, but it happens all the time. Certainly, what we consider a reasonable growth rate is not projected on a sequential basis going forward. | Medpace is continuing to hire, which management views as a signal of confidence. The company has seen improved retention rates, contributing to operating efficiencies. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-07-22 | Medpace reported a strong Q2 2026 with record net bookings (up 28.2%), a 1.13x book-to-bill, and significantly reduced cancellations. Management upgraded 2026 guidance and noted a favorable shift to oncology in new awards, balancing prior metabolic concentration. The stock surged 13.95% (outperforming SPY), indicating strong market approval of the robust performance and positive outlook. | Earnings Transcript | Positive | +13.95% (vs SPY: +15.08%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| MEDP_54a92808 | over the next few quarters | 2026-04-01 | 2026-12-31 | Outcome of Medpace's initiatives to expand its pipeline of opportunities and improve its win rate, and the resulting trend in cancellation rates and net new business awards. | High cancellation rates and weak gross bookings have led to a low book-to-bill ratio and raise concerns about future revenue growth. Success in these initiatives is critical to improving backlog and restoring a desired growth profile. | Ticker | 2026-04-22 | earnings_transcript |
| MEDP_295080d7 | end the year lower than what we started this year at | 2026-04-22 | 2026-12-31 | Realization of management's expectation for pass-through revenues to decrease as a percentage of total revenue, driven by the winding down of some metabolic studies. | A decrease in the proportion of pass-through revenues, which typically have lower margins, could positively impact the company's overall EBITDA margin and the quality of its revenue. | Ticker | 2026-04-22 | earnings_transcript |
| MEDP_e1f9490e | a few years out | 2028-01-01 | 2029-12-31 | Medpace achieving net financial benefits from its investments in Artificial Intelligence (AI) initiatives. | While AI is a significant industry trend, management expects that investments in AI will outweigh efficiency gains for at least the next two years, impacting the timeline for any positive financial contribution from AI. | Ticker | 2026-04-22 | earnings_transcript |
| MEDP_f4e43f3e | not in the near term | 2026-07-01 | 2027-04-22 | Medpace appoints a new President to succeed Jesse Geiger, who is departing. | The appointment of a new President is a key leadership transition that could influence strategic direction, operational execution, and investor confidence, despite management's assurance of a strong team. | Ticker | 2026-04-22 | earnings_transcript |
| MEDP_56dbc696 | second quarter, over the next few quarters | 2026-04-01 | 2027-03-31 | Trend in Medpace's backlog cancellation rates and net book-to-bill ratio. | A sustained high cancellation rate and a book-to-bill ratio below 1.0 would continue to pressure future revenue growth and investor sentiment. An improvement would signal a healthier demand trajectory. | Ticker | 2026-04-23 | earnings_transcript |
| MEDP_b929f82b | over the next few quarters, immediate term | 2026-04-01 | 2027-03-31 | Outcome of Medpace's initiatives to expand its pipeline of opportunities and improve its win rate. | Successful implementation could combat high cancellation rates and drive an increase in gross awards, which is crucial for restoring a desired growth rate and improving bookings. | Ticker | 2026-04-23 | earnings_transcript |
| MEDP_8751ce1e | 2026 guidance, 2027 | 2026-04-23 | 2027-12-31 | Medpace's ability to meet its reconfirmed 2026 financial guidance and the actual sequential revenue growth trajectory in 2027. | Achieving 2026 guidance would affirm management's confidence, while the 2027 sequential growth will be a key indicator of the company's long-term growth profile and impact valuation. | Ticker | 2026-04-23 | earnings_transcript |
| MEDP_2ffd1934 | end the year lower than what we started this year at | 2026-04-23 | 2026-12-31 | Whether pass-through costs as a percentage of revenue decrease by year-end 2026 as projected by management. | A reduction in pass-throughs could positively impact EBITDA margins, while a failure to decrease could put pressure on profitability. | Ticker | 2026-04-23 | earnings_transcript |
| MEDP_d72516b1 | next 2 years at least (for investment), a few years out (for net benefit) | 2026-04-23 | 2029-04-23 | Realization of net efficiency benefits from Medpace's ongoing investments in AI. | Significant net benefits from AI could enhance long-term operational efficiency and profitability, while a slower-than-expected realization could impact future cost structures. | Ticker | 2026-04-23 | earnings_transcript |